Hangzhou Highlightll Pharmaceutical Co., Ltd
Clinical trials sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New arthritis drug TLL-018 moves to Long-Term safety check in 350 patients Results expected Dec 2026 (estimated)
- New eczema ointment shows promise in early trial Results expected Jun 2027 (estimated)
- Can a new pill tame rheumatoid arthritis when standard drugs fail? Results expected Jul 2027 (estimated)
-
New arthritis drug TLL-018 moves to Long-Term safety check in 350 patients
Disease control Recruiting nowThis study is checking the long-term safety and effectiveness of an experimental drug called TLL-018 for people with rheumatoid arthritis. It is for adults who have already finished a previous study of this drug. The goal is to see how well the drug controls arthritis symptoms ov…
Phase 3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New eczema ointment shows promise in early trial
Symptom relief Recruiting nowThis study tests an ointment called HL-300 in people with mild-to-moderate atopic dermatitis (eczema). About 156 adults will apply the ointment or a placebo twice daily for 4 weeks. Researchers will check if the ointment reduces eczema severity and improves symptoms.
Phase 1/2 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC